Electromed, a medical device company specialising in airway clearance therapy products, has signed an agreement with Monaghan Medical to distribute and sell its Aerobika oscillating positive expiratory pressure (OPEP) device in the US homecare market.
Aerobika OPEP is a drug-free, hand-held device that provides airway clearance therapy for patients with compromised pulmonary function. With a proprietary pressure-oscillation dynamic, it opens weak or collapsed airways and assists in mucociliary clearance.
Sale of the device in targeted geographies will begin in Q3 2017, with planned expansion before the end of the year.
Molecular diagnostics company, Asuragen, has signed a collaboration agreement with Thermo Fisher Scientific for the development and commercialisation of capillary electrophoresis-based in-vitro diagnostics (IVDs).
Pursuant to the agreement, Asuragen will use its AmplideX PCR/CE products that are built under design control and manufactured in its cGMP facility, to develop diagnostic kits for Thermo Fisher’s 3500 Dx series genetic analyser CS2 instrument.
Further, Asuragen’s analytics will be integrated with its reporting suite, the AmplideX Reporter, to provide a sample-to-answer solution.
Molecular diagnostic tests and pathology services provider, Interpace Diagnostics, has announced the initiation of a collaborative research programme with cancer dialysis company, Viatar CTC Solutions.
The programme, which was initiated to detect and characterise early cancer in liquid biopsies, will combine Viatar's novel circulating tumour cell collection technology and Interpace’s PancraGEN assay, a pancreatic cyst molecular test that uses a small sample of pancreatic cyst fluid to detect pancreatic cancer or its likeliness.
Lantheus Medical Imaging has signed a term sheet agreement with GE Healthcare for the worldwide development and commercialisation of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD).
The agreement involves continued development of flurpiridaz, whose Phase-3 clinical study, worldwide regulatory approvals, launch and commercialisation will funded by GE in collaboration with LMI, which will participate in both development and commercialisation of the agent through a joint steering committee.
LMI will also co-promote the agent in the US, while GE will focus on obtaining regulatory approval in the US, Japan, Europe and Canada.
The companies are expected sign a definitive agreement in Q2 2017 following necessary approvals.
Hemostatic and wound care devices developer, Arch Therapeutics, intends to raise gross proceeds of approximately $6.1m through direct offering of 10,166,664 units, each comprising one common stock share and 0.55 of a Series F Warrant, to purchase one share of common stock.
The Series F warrants have an exercise price of 75 cents a share and are exercisable for a period of five years.
The company intends to use approximately $825,000 of the offering proceeds to clear its indebtedness to the Massachusetts Life Sciences Center (MLSC).
Vention Medical has signed a definitive agreement to sell its advanced technologies business, Vention AT, to Nordson Corp for $705m in cash.
Vention AT designs, develops and manufactures minimally-invasive medical delivery devices, catheters and advanced components.
The acquisition, which is expected to be completed during Nordson’s second fiscal quarter, will enable the company to become a leader in minimally-invasive delivery markets, enhance its strategic manufacturing and product capabilities, and provide presence in key medical markets.
Upon closing the deal, the target company will become part of Nordson’s Advanced Technology Systems segment.
Image: Electromed’s Aerobika OPED device. Photo: Business Wire.